COSM Cosmos Health Inc.
Price Chart
Executive Summary
Cosmos Health's subsidiary Cana Laboratories acquired international patent application WO2025108566A1 from Cloudpharm P.C. and plans expanded nanotechnology investments. The deal adds early-stage IP to Cosmos's portfolio but lacks disclosed financial terms, FDA catalyst, or near-term revenue impact — making it an early-stage R&D step with limited immediate valuation effect.
Actionable Insight
Monitor Cosmos for the next quarterly filing (10-Q) detailing R&D expense associated with the nanotechnology initiative and any patent-office updates. Without disclosed deal economics or revenue guidance, this filing does not alter near-term financial projections.
Key Facts
- Cana Laboratories acquired patent application WO2025108566A1 from Cloudpharm P.C.
- Patent protection being pursued at national/regional levels across key international markets.
- Technology targets pharma, nutraceutical, OTC, and specialized healthcare products.
- Cana Laboratories is European GMP-licensed and EMA-certified.
- No financial terms (deal value, upfront, milestones) disclosed.
- No revenue contribution or commercial launch timeline provided.
Financial Impact
Undisclosed — no consideration, milestones, or revenue projections provided in the release.
Risk Factors
- Patents remain at application stage — no guarantee of grant or commercial viability.
- No disclosed cash outflow or financing commitment could create future dilution if R&D spend escalates.
- Micro-cap liquidity ($15M market cap) amplifies downside if IP fails to monetize.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308237 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Press Release
| $0.2086 awaiting T+5 | awaiting T+5 | — | $0.2100 (+0.67%) |
|
Jun 12, 2026
today
|
Press Release
| $0.2262 awaiting T+5 | awaiting T+5 | — | $0.2100 (−7.16%) |
|
Jun 10, 2026
2d ago
|
Press Release
| $0.1994 awaiting T+5 | awaiting T+5 | — | $0.2100 (+5.32%) |
|
Jun 9, 2026
3d ago
|
Press Release
| $0.2183 awaiting T+5 | awaiting T+5 | — | $0.2100 (−3.80%) |
|
Jun 8, 2026
4d ago
|
Press Release
| $0.2290 awaiting T+5 | awaiting T+5 | — | $0.2100 (−8.30%) |
|
Jun 6, 2026
7d ago
|
S-3/A
| $0.2800 awaiting T+5 | awaiting T+5 | — | $0.2100 (+25.00%) |
|
Jun 5, 2026
7d ago
|
DEFA14A
| $0.2520 awaiting T+5 | awaiting T+5 | — | $0.2100 (−16.67%) |
|
Jun 1, 2026
12d ago
|
Press Release
| $0.2530 $0.2510 | ▼ −0.79% | ▲ +1.96% | $0.2100 (−17.00%) |
|
May 26, 2026
17d ago
|
Press Release
| $0.2630 $0.2530 | ▼ −3.80% | ▼ −4.89% | $0.2100 (−20.15%) |
|
May 22, 2026
21d ago
|
8-K
| $0.2530 $0.2526 | ▼ −0.16% | ▼ −1.83% | $0.2100 (−17.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access